Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013395 (dyspepsia)
 4,879 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Strontium ranelate (SR) is a new drug for osteoporosis that has a unique effect profile, being antiresorptive as well as anabolic. In postmenopausal women with spinal osteoporosis pretreated with calcium and vitamin D, SR reduced the risk of new vertebral fractures after 1 year by 49% and after 3 years by 41% (NNT = 9). The numbers of clinical fractures were in the same periods reduced by 52% and 38%, respectively. The number of patients with more than one new spinal fracture was reduced by 36%. Height reduction was less among the patients so treated, and there was a tendency towards less lumbar pain. Measured lumbar BMD increased 14.4% over three years, corresponding to an increase of 6.8% after adjustment for bone strontium content, compared with a decrease in the placebo group of 1.3%. The risk of new non-vertebral fractures was reduced by 16%. Among elderly women with a hip T-score <-3, SR decreased the risk of hip fractures by 36% over three years (NNT = 48). In patients with osteopenia and at least one clinical risk factor, SR reduced the risk of first vertebral fracture by 72% over three years (NNT = 12). In patients over 80 years of age, the risk of new vertebral fractures was reduced by 32% (NNT = 14). There were few side effects. SR is thus suitable for reducing the risk of vertebral and hip fractures from postmenopausal osteoporosis, especially among patients with upper abdominal dyspepsia and the elderly.
 ...
PMID:[Strontium ranelate: a new therapeutic principle for postmenopausal osteoporosis]. 1615 55

Hypercalcemia associated with breast cancer arises either from metastatic bone disease or from paraneoplastic secretion of parathyroid hormone-related peptide. We report a female 69-year-old patient with invasive intraductal breast cancer and hypercalcemia (3,4 mmol/l) referred to endocrinologist. Standard care in oncology was refused and with respect to the presence of estrogenic receptors the patient accepted only antiestrogenic treatment. Bone scan revealed no skeletal metastasis. Entry laboratory exam confirmed hypercalcemia, hypophosphatemia and significantly elevated parathyroid hormone (793 ng/l). The patient complained of bone pain and dyspepsia. Neck ultrasound showed a multinodular goiter with particularly enlarged left lobe. Parathyroid gland scintigraphy revealed a possible parathyroid adenoma behind the lower pole of the left thyroid lobe. The patient underwent thyroidectomy with an excision of the parathyroid mass. Microscopic examination identified a benign adenomatous goitre and benign parathyroid adenoma. Postoperatively, both serum calcium and parathyroid hormone normalized. Replacement of calcium and vitamin D were initiated both with bisphosphonate with regard to newly diagnosed osteoporosis. This case demonstrates a patient with breast cancer and hypercalcemia unrelated to the malignant disease. Primary hyperparathyroidism should be considered as a possible cause of hypercalcemia in breast cancer patients in the setting of negative bone scan, elevated parathyroid hormone and mildly deteriorated bone mineral density.
 ...
PMID:[Primary hyperparathyroidism as a cause of hypercalcemia in a patient with breast cancer]. 2139 55